Figure EV5. Tumor‐PeSC crosstalk affects the immune system.

• A, B
  In vivo neutralization of CD106: (A) Experiment setting. (B) Tumor weight, FACS analysis of % PeSC⁺ among CD45⁻ cells, % Epi⁺ among CD45⁻ cells, % CD11b⁺ among CD45⁺ cells, % Ly6G⁺CD11b⁺ among CD45⁺ cells, % CD11b⁺F4/80⁺ among CD45⁺ cells, % CD11b⁺F4/80⁺CD103⁺ among CD45⁺ cells (eight mice in each group, five for FACS analysis, and three for histological analysis. Quantification of PeSCs and Epi cells were cumulative from two FACS panels as technical duplicates).
• C–L
  In vivo depletion of CCL5 impact the macrophages differentiation: (C) Experimental setting. (D) Tumor weight of the grafts formed by Epi + PeSC in CCL5‐depleted conditions compared with undepleted conditions. FACS analysis of the percentage of CD11b⁺ cells (E), Ly6G⁺CD11b⁺ (F), F4/80⁺CD11b⁺ (G), F4/80⁺CSFR1⁺ (H), F4/80⁺CD163⁺ (I), F4/80⁺CD11b⁺CD103⁺ (J), F4/80⁺CD11b⁺PD‐L1⁺ (K) and CD8⁺ cells (L) among CD45⁺ cells derived from the tumor grafts. Ten mice in each group, six for FACS analysis and four for histological analysis.

Data information: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. The P‐values were calculated using Student's t‐test.